As the debate over pharmaceutical pricing heats up, Brinker Harding, an Omaha city councilor and congressional candidate, finds himself at the center of attention. Despite his significant investments in the pharmaceutical industry, Harding is promising to advocate for reduced drug costs.
In the race for Nebraska’s 2nd District congressional seat, Harding, a Republican, is facing off against Denise Powell, a small business owner representing the Democratic Party. On August 4, Harding took to social media to declare his support for a policy aimed at lowering drug prices, echoing a proposal endorsed by former President Donald Trump.
This policy suggests aligning Medicaid payment rates for certain medications with those of other nations to potentially save billions for the federal government. However, critics argue it might not effectively diminish the pharmaceutical industry’s influence over prices or result in reduced costs for consumers.
Harding has previously expressed his views in a January op-ed for the Omaha World-Herald, where he voiced his opposition to “subsidizing big pharma and big insurance with taxpayer-funded bailouts.”
Nevertheless, personal finance disclosures reveal that Harding and his spouse possess investments ranging up to $125,000 in major pharmaceutical companies like Pfizer and AbbVie. Both firms have faced legal challenges for price inflation and alleged profiteering.
Although Pfizer and AbbVie agreed to a voluntary most-favored nation pricing pact with the Trump administration last year, both companies proceeded to increase drug prices in 2026.
Health care costs remain a pivotal issue in this election cycle. Powell is advocating for a policy to limit insulin expenses to $35 monthly for all Americans.
The post Brinker Harding has up to $125,000 invested in Big Pharma appeared first on American Journal News.
